Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab vs Conventional Induction in Renal Transplant (INTAC)
NCT00113269Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- May 2005
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alemtuzumab in kidney transplant rejection (4 arms), sponsored by Astellas Pharma. Primary endpoint: Biopsy-confirmed Acute Rejection at 6 months. Started May 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00113269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113269.